Biodesix INC Form 4 insider transactions

Biodesix's CFO, Robin Harper Cowie, was granted 29,000 stock options with an exercise price of $6.46, vesting monthly over four years.

Biodesix's Chief Accounting Officer, Chris Vazquez, was granted 12,000 stock options with an exercise price of $6.46, vesting over four years.

BIODESIX Chief Accounting Officer Chris Vazquez reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Biodesix Chief Development Officer Gary Pestano filed a Form 4 detailing the automatic sale of 23 common shares to cover taxes following the vesting of 69 restricted stock units.

BIODESIX Chief Commercial Officer Kieran O'Kane reported the acquisition of common stock through RSU vesting and a subsequent sale to cover taxes.

BIODESIX President & CEO Scott Hutton reported the acquisition of shares from RSU vesting and a subsequent sale to cover taxes, following a recent reverse stock split.

BIODESIX CFO Robin Harper Cowie reported the acquisition of 158 common shares from RSU vesting and the sale of 50 shares to cover taxes, adjusted for a recent reverse stock split.

Biodesix Chairman John Patience reports changes in his beneficial ownership of common stock and restricted stock units following a reverse stock split and RSU vesting.

Jack W. Schuler, a Director and 10% Owner of BIODESIX INC, acquired 142,045 shares of common stock for $7.04 per share, totaling approximately $1 million, under a pre-arranged trading plan.

BIODESIX Director and 10% owner Jack W. Schuler acquired additional common stock through trusts following a recent one-for-twenty reverse stock split.

Biodesix Director and 10% owner Jack W. Schuler acquired over 3.4 million shares of common stock through a pre-planned transaction, increasing his beneficial ownership.

BIODESIX CFO Robin Harper Cowie sold 988 shares of common stock to cover tax obligations following the vesting of restricted stock units.

BioDesix Inc. CEO Scott Hutton reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

BioDesix Chief Commercial Officer Kieran O'Kane reported the vesting of 1,489 restricted stock units and the subsequent sale of 476 shares to cover tax obligations.

BioDesix Chief Development Officer Gary Pestano sold 442 shares of common stock to cover taxes following the vesting of restricted stock units.

BIODESIX Chief Accounting Officer Chris Vazquez reported the vesting of restricted stock units and a subsequent sale of shares to cover taxes.

John Patience, Chairman and Director of Biodesix Inc., reported the conversion of restricted stock units into common stock, updating his direct and indirect beneficial ownership.

BIODESIX Director Hany Massarany reported the conversion of 26,368 restricted stock units into common stock, increasing his direct beneficial ownership to 310,135 shares.

Director Matthew Strobeck reports acquisition of restricted stock units and stock options in Biodesix Inc.

John Patience, Chairman of Biodesix Inc., reports the acquisition of restricted stock units and stock options.

Director Hany Massarany reports acquisition of restricted stock units and stock options in Biodesix Inc. on May 20, 2025.

Director Lawrence T. Kennedy Jr. reports acquiring restricted stock units and stock options in Biodesix Inc. on May 20, 2025.

Director Jon Faiz Kayyem reports acquisition of restricted stock units and stock options in Bio-Rad Laboratories.

Director Jean Franchi reports the acquisition of restricted stock units and stock options in Biodesix Inc. on May 20, 2025.

Director Jack W. Schuler reports purchasing additional Biodesix shares through multiple transactions, increasing his indirect holdings.

Chris Vazquez, Chief Accounting Officer of Bio-Rad Laboratories (BDSX), reported the sale of common stock to cover taxes upon the vesting of restricted stock units (RSUs).

Gary Pestano, Chief Development Officer of Biodesix Inc., reports the sale of common stock to cover taxes upon the vesting of restricted stock units (RSUs).

Kieran O'Kane, Chief Commercial Officer of Bio-Rad Laboratories, reports the vesting of restricted stock units and subsequent sale of shares to cover taxes.

Biodesix CEO Scott Hutton sold shares of common stock to cover taxes upon the vesting of restricted stock units (RSUs).

Robin Harper Cowie, CFO, Secretary, and Treasurer of Bio-Rad Laboratories, reports the sale of common stock to cover taxes upon the vesting of Restricted Stock Units (RSUs).